The estimated Net Worth of Christoph Lengauer is at least $3.73 millió dollars as of 13 April 2016. Christoph Lengauer owns over 15,872 units of Hookipa Pharma Inc stock worth over $299,149 and over the last 9 years he sold HOOK stock worth over $3,266,037. In addition, he makes $168,207 as Independent Director at Hookipa Pharma Inc.
Sign up
Christoph Lengauer HOOK stock SEC Form 4 insiders trading
Christoph has made over 5 trades of the Hookipa Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 15,872 units of HOOK stock worth $317,599 on 13 April 2016.
The largest trade he's ever made was selling 84,998 units of Hookipa Pharma Inc stock on 2 November 2015 worth over $1,789,208. On average, Christoph trades about 15,455 units every 15 days since 2015. As of 13 April 2016 he still owns at least 56,657 units of Hookipa Pharma Inc stock.
You can see the complete history of Christoph Lengauer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christoph Lengauer biography
Dr. Christoph Lengauer Ph.D. serves as Independent Director of the Company. Dr. Lengauer has been a partner at Third Rock Ventures since May 2019 and was previously a venture partner from January 2016 to May 2019. Dr. Lengauer has served as founding Chief Innovation Officer at Thrive Early Detection since April 2019. He has been the Chief Scientific Officer of Celsius Therapeutics from April 2018 till April 2020. He has been the Executive Vice President of Blueprint Medicines since November 2016, where he was previously the Chief Scientific Officer and Chief Drug Hunter from January 2012 to November 2016, the Vice President and Global Head of Oncology Drug Discovery and Preclinical Development at Sanofi S.A., a multinational pharmaceutical company, from May 2008 to January 2012 and Executive Director and Senior Unit Head of Oncology Discovery at the Novartis Institutes for Biomedical Research from July 2005 to May 2008. Prior to his experience at Novartis, Dr. Lengauer was a member of the faculty at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine from 1997 to 2005. Our Board of Directors believes that Dr. Lengauer's experience in biopharmaceutical research and development and his experience in venture capital qualify him to serve on our Board of Directors.
What is the salary of Christoph Lengauer?
As the Independent Director of Hookipa Pharma Inc, the total compensation of Christoph Lengauer at Hookipa Pharma Inc is $168,207. There are 11 executives at Hookipa Pharma Inc getting paid more, with Joern Aldag having the highest compensation of $6,367,980.
How old is Christoph Lengauer?
Christoph Lengauer is 55, he's been the Independent Director of Hookipa Pharma Inc since 2018. There are 6 older and 11 younger executives at Hookipa Pharma Inc. The oldest executive at Hookipa Pharma Inc is Prof. Rolf M. Zinkernagel M.D., Ph.D., 77, who is the Co-Founder.
What's Christoph Lengauer's mailing address?
Christoph's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10118.
Insiders trading at Hookipa Pharma Inc
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... és Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
What does Hookipa Pharma Inc do?
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
What does Hookipa Pharma Inc's logo look like?
Complete history of Christoph Lengauer stock trades at Blueprint Medicines Corp és Hookipa Pharma Inc
Hookipa Pharma Inc executives and stock owners
Hookipa Pharma Inc executives and other stock owners filed with the SEC include:
-
Joern Aldag,
Chief Executive Officer, Director -
Reinhard Kandera,
Chief Financial Officer, Director -
Igor Matushansky,
Chief Medical Officer and Global Head of Research and Development -
Joern Aldag,
CEO & Director -
Dr. Igor Matushansky M.D., Ph.D.,
Chief Medical Officer and Global Head of R&D -
Dr. Reinhard Kandera,
CFO & Director -
Sander van Deventer,
Independent Director -
Graziano Seghezzi,
Independent Director -
Jan van de Winkel,
Independent Chairman of the Board -
Michael Kelly,
Independent Director -
David Kaufman,
Independent Director -
Christoph Lengauer,
Independent Director -
Julie O Neill,
Independent Director -
Jean-Charles Soria,
Director -
Roman Necina,
Chief Technology Officer -
Klaus Orlinger,
Executive Vice President - Research -
Dr. Klaus Orlinger Ph.D.,
Exec. VP of Research -
Nina Waibel,
Sr. Director of Communications -
Marine Popoff,
Communications & Investor Relations Mang. -
Dr. Roman Necina Ph.D.,
Chief Technology Officer -
Lukas Flatz,
Co-Founder -
Andreas Bergthaler,
Co-Founder -
Prof. Rolf M. Zinkernagel M.D., Ph.D.,
Co-Founder -
Jerry D Jones,
Director -
Bros. Advisors Lp Baker Bro...,
-
Capital Fund Ii Cooperatief...,
10% owner -
David Pinschewer,
Chief Scientific Officer -
Group, Llc Green Jeremy Red...,
-
Capital Vi Fcpr Sofinnova P...,
-
Anders Lilja,
Sr. VP, Technical Development -
Timothy P. Reilly,
-
Andrew R Goeler,
Director -
Mark D Moreland,
Chief Financial Officer -
John D Jr Rogers,
Director -
Martin J Iv Wall,
Vice President, Sales -
David R Lord,
Director -
V Sebastian Pastore,
VP, Brewing Operations & Tech -
Marc J Cramer,
Director -
Terry E Michaelson,
Co-Chief Executive Officer -
Kurt R Widmer,
Director -
Danielle A Katcher,
Vice President, Marketing -
Kevin R Kelly,
Director -
Timothy P Boyle,
Director -
David J Mickelson,
President & COO -
Companies, Inc.Busch Invest...,
-
Frank H Clement,
Director -
Ann G Widmer,
10% owner -
Anthony J Short,
Director -
Kurt R Widmer Ann G Widmer,
-
Paul S Shipman,
President & CEO -
Michael Loughran,
Director -
Katia Schlienger,
Chief Medical Officer -
Jorn Aldag,
Chief Executive Officer -
Christine D. Baker,
Chief Operating Officer -
Mark Winderlich,
Chief Development Officer -
Mary Theresa Coelho,
EVP and CFO -
Malte Peters,
Chief Executive Officer -
Sean A Cassidy,